Two studies showed that renal cell cancer patients had significantly better outcomes when their treatment combined the targeted therapy drug axitinib, or Inlyta, with an immunotherapy -- one study used pembrolizumab, or Keytruda, and the other used avelumab, or Bavencio.
from CNN.com - RSS Channel https://cnn.it/2tpK9ji
via
No comments:
Post a Comment